Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-escalation Study of NK012 Administered Intravenously as a Single Dose Every Three Weeks in Patients With Refractory Solid Tumors

NCT00542958 is registered in ClinicalTrials.gov with Nippon Kayaku Co., Ltd. as lead sponsor.

NCT NCT00542958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00542958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-escalation Study of NK012 Administered Intravenously as a Single Dose Every Three Weeks in Patients With Refractory Solid Tumors
Lead sponsor
Nippon Kayaku Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2011
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer